

May 14, 2021

Estela Raychaudhuri  
President  
InBios International, Inc.  
307 Westlake Ave N, Suite 300  
Seattle, WA 98109

Device: SCoV-2 *Detect* IgG ELISA  
EUA Number: EUA201632  
Company: InBios International, Inc.  
Indication: Qualitative detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (dipotassium EDTA) run manually or using the Dynex DSX Automated ELISA System. Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Emergency use of this test is limited to authorized laboratories.  
Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate (automated method) or high (manual and automated methods) complexity tests.

Dear Ms. Raychaudhuri:

On June 10, 2020, based on your<sup>1</sup> request, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of the SCoV-2 Detect IgG ELISA pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3) for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum. Your product was intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Testing was limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet the requirements to perform high complexity tests.

On August 17, 2020, you requested to revise your EUA. Based on that request, and having concluded that revising the June 10, 2020 EUA is appropriate to protect the public health or

---

<sup>1</sup> For ease of reference, this letter will use the term “you” and related terms to refer to InBios International, Inc.

safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the June 10, 2020, letter in its entirety with the revisions incorporated.<sup>2</sup> Pursuant to section 564 of the Act and the Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product<sup>3</sup> is hereby authorized for use consistent with the indication described above.

On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.<sup>4</sup>

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA relied upon is included in the “SCoV-2 *Detect* IgG ELISA” Instructions for Use (identified below).

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.

## **I. Criteria for Issuance of Authorization**

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

---

<sup>2</sup> The revisions to the June 10, 2020, letter and authorized labeling include: (1) modification of the intended use to add plasma (dipotassium EDTA) as an authorized specimen type, include testing with the of Dynex DSX Automated ELISA System for use in automating the assay, addition of testing at laboratories certified under CLIA that meet requirements to perform moderate complexity tests (using the automated method) and other updates to reflect language used in more recent authorizations, (2) update the healthcare provider (HCP) and recipient fact sheets to include information regarding testing of individuals who have received a COVID-19 vaccine, and update the HCP fact sheet to include information related to performance with circulating variants, (3) update the Instructions for Use to change the Cut-Off Control OD requirement to greater than the negative control OD, change the format of the kit expiration date, update the PPA of the assay based on testing of additional individuals, add limitations related to testing of individuals who have received a COVID-19 vaccine, performance with circulating variants, and related to specimen types and automated testing, and other minor edits to reflect language used in more recent authorizations, (4) update the Conditions of Authorization to remove Condition H, Condition T (condition fulfilled), consolidate several conditions in new Condition K. and other clarifying modifications to reflect language used in more recent authorizations and (5) updated the device name from SCoV-2 Detect IgG ELISA to SCoV-2 *Detect* IgG ELISA.

<sup>3</sup> For ease of reference, this letter will use the term “your product” to refer to the SCoV-2 Detect IgG ELISA for the indication identified above.

<sup>4</sup> U.S. Department of Health and Human Services, *Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3. 85 FR 7316 (February 7, 2020).

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing recent or prior infection with SARS-CoV-2 by identifying individuals with an adaptive immune response to the virus that causes COVID-19, and that the known and potential benefits of your product when used for such use, outweigh the known and potential risks of your product; and
3. There is no adequate, approved, and available alternative to the emergency use of your product.<sup>5</sup>

## II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

### Authorized Product Details

Your product is an in vitro diagnostic test for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum or plasma (dipotassium EDTA) run manually or using the Dynex DSX Automated ELISA System (includes the Dynex DSX Automated ELISA System Operator Manual). Your product is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Testing is limited to laboratories certified under CLIA, 42 U.S.C. 263a, that meet requirements to perform moderate (automated method) or high (manual and automated methods) complexity tests. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity.

The SCoV-2 *Detect* IgG ELISA is a qualitative enzyme-linked immunosorbent assay (ELISA) for the detection of IgG antibodies targeting epitopes derived from SARS-CoV-2. Diluted serum specimens are added to antigen-coated wells and incubated. After incubation and washing, human antibodies targeting SARS-CoV-2 antigens remain bound to the plate surface. Secondary antibody conjugated to horseradish peroxidase (HRP) targeting human IgG is then added to each well. After incubation, the ELISA wells are washed once again and the captured HRP conjugated secondary antibody is detected by a colorimetric reaction. The Optical Density (OD) at 450 nm is read and divided by the OD<sub>450</sub> of the cut-off sample to give a value for immunological status ratio (ISR) for the sample.

$ISR \leq 0.9$  Negative result indicating no detectable IgG against SARS-CoV-2 detected. The result does not rule out the possibility of SARS-CoV-2 infection.

$0.9 < ISR < 1.1$  Re-test sample according to Instruction for Use.

$ISR \geq 1.1$  Positive result indicating detectable IgG against SARS-CoV-2 detected.

---

<sup>5</sup> No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.

The assay steps outlined above can be performed manually using existing laboratory equipment or it can be automated on the Dynex DSX Automated ELISA System.

Your product includes the following materials or other authorized materials: SCoV-2 Antigen Coated Microtiter Strips for IgG, SCoV-2 IgG Negative Control, SCoV-2 IgG Positive Control, SCoV-2 IgG Cut-Off Control, Sample Dilution Buffer for SCoV-2, 100X Conjugate for SCoV-2 IgG, Conjugate Diluent for SCoV-2, 10X Wash Buffer, Liquid TMB Substrate, and Stop Solution.

For quality control, your product includes the SCoV-2 IgG Positive Control, SCoV-2 IgG Negative Control and the SCoV-2 IgG Cut-Off Control, or other authorized control materials (as may be requested under Condition K below), to ensure the integrity of the kit reagents and to determine the assay specific threshold, which are run as outlined in the Instructions for Use, described below. Your product also requires the use of additional authorized materials and authorized ancillary reagents that are not included with your product and are described in the Instructions for Use.

The above described product is authorized to be accompanied with the labeling entitled “SCoV-2 *Detect* IgG ELISA” Instructions for Use (available at <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas>), and the following product-specific information pertaining to the emergency use (collectively referenced as “authorized labeling”), which is required to be made available to healthcare providers and recipients:

- Fact Sheet for Healthcare Providers: InBios International, Inc. – SCoV-2 *Detect* IgG ELISA
- Fact Sheet for Recipients: InBios International, Inc. – SCoV-2 *Detect* IgG ELISA

The above described product, when accompanied by the authorized labeling, is authorized to be distributed to and used by authorized laboratories under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing recent or prior infection with SARS-CoV-2 by identifying individuals with an adaptive immune response to the virus that causes COVID-19, when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

### **III. Waiver of Certain Requirements**

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, storage, and distribution of your product, but excluding Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).

### **IV. Conditions of Authorization**

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:

#### **InBios International, Inc. (You) and Authorized Distributor(s)<sup>6</sup>**

- A. Your product must comply with the following labeling requirements under FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).
- B. You and authorized distributor(s) must make your product available with the authorized labeling to authorized laboratories.
- C. You and authorized distributor(s) must make available on your website(s) the Fact Sheet for Healthcare Providers and the Fact Sheet for Recipients.
- D. You and authorized distributor(s) must inform authorized laboratories and relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your product and authorized labeling.

---

<sup>6</sup> “Authorized Distributor(s)” are identified by you, InBios International, Inc., in your EUA submission as an entity allowed to distribute your product.

- E. Through a process of inventory control, you and authorized distributor(s) must maintain records of the authorized laboratories to which they distribute your product and number they distribute.
- F. You and authorized distributor(s) must collect information on the performance of your product. You must report to the Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) (via email: CDRH-EUA- Reporting@fda.hhs.gov) any suspected occurrence of false positive and false negative results and significant deviations from the established performance characteristics of the product of which you become aware.
- G. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.

**InBios International, Inc. (You)**

- H. You must notify FDA of any authorized distributor(s) of your product, including the name, address, and phone number of any authorized distributor(s).
- I. You must provide authorized distributor(s) with a copy of this EUA and communicate to authorized distributor(s) any subsequent amendments that might be made to this EUA and its authorized accompanying materials (e.g., Fact Sheets).
- J. You must comply with the following requirements pursuant to FDA regulations: 21 CFR Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).
- K. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling, and not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to DMD/OHT7-OIR/OPEQ/CDRH and require appropriate authorization from FDA prior to implementation.
- L. You must evaluate the performance and assess traceability<sup>7</sup> of your product with any FDA-recommended reference material(s) or established panel(s) of characterized

---

<sup>7</sup> Traceability refers to tracing analytical sensitivity/reactivity back to an FDA-recommended reference material. FDA may request, for example, that you perform this study in the event that we receive reports of adverse events concerning your product.

clinical specimens. After submission to and concurrence with the data by FDA, you must update your labeling to reflect the additional testing. Such labeling updates will be made in consultation with, and require concurrence of, DMD/OHT7-OIR/OPEQ/CDRH.

- M. You must have a process in place to track adverse events, including any occurrence of false results, and report to FDA pursuant to 21 CFR Part 803.
- N. You must have lot release procedures and the lot release procedures, including the study design and statistical power, must ensure that the tests released for distribution have the clinical and analytical performance claimed in the authorized labeling.
- O. If requested by FDA, you must submit lot release procedures to FDA, including sampling protocols, testing protocols, and acceptance criteria, that you use to release lots of your product for distribution in the U.S. If such lot release procedures are requested by FDA, you must provide it within 48 hours of the request.
- P. If requested by FDA, you must periodically submit new lots for testing at the National Cancer Institute, or by another government agency designated by FDA, to confirm continued performance characteristics across lots. In addition, FDA may request records regarding lot release data for tests to be distributed or already distributed. If such lot release data are requested by FDA, you must provide it within 48 hours of the request.
- Q. You must complete the agreed upon real-time stability study for your product. After submission to and concurrence with the data by FDA, you will update your labeling to reflect the additional testing. Such labeling updates will be made in consultation with, and require concurrence of, DMD/OHT7-OIR/OPEQ/CDRH.

#### **Authorized Laboratories**

- R. Authorized laboratories using your product must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- S. Authorized laboratories must use your product as outlined in the authorized labeling. Deviations from the authorized procedures, including the authorized instrument, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.
- T. Authorized laboratories that receive your product must notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- U. Authorized laboratories using your product must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.

- V. Authorized laboratories must collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: [CDRH-EUA-Reporting@fda.hhs.gov](mailto:CDRH-EUA-Reporting@fda.hhs.gov)) and to you (<https://inbios.com/technical-support>) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your product of which they become aware.
- W. All laboratory personnel using your product must be appropriately trained in immunoassay techniques and use appropriate laboratory and personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling. All laboratory personnel using the assay must also be trained in and be familiar with the interpretation of results of the product.

**InBios International, Inc. (You), Authorized Distributor(s) and Authorized Laboratories**

- X. You, authorized distributor(s), and authorized laboratories using your product must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

**Conditions Related to Printed Materials, Advertising and Promotion**

- Y. All descriptive printed matter, advertising, and promotional materials relating to the use of your product, shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and meet the requirements set forth in section 502(a), (q)(1), and (r) of the Act and FDA implementing regulations.
- Z. No descriptive printed matter, advertising, or promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.
- AA. All descriptive printed matter, advertising, and promotional materials relating to the use of your product shall clearly and conspicuously state that:
- This product has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
  - This product has been authorized only for detecting the presence of IgG antibodies to SARS-CoV-2, not for any other viruses or pathogens; and
  - The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.



**V. Duration of Authorization**

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

---

RADM Denise M. Hinton  
Chief Scientist  
Food and Drug Administration

Enclosure